Vanguard Group Inc. Raises Position in Xencor, Inc. $XNCR

Vanguard Group Inc. lifted its position in shares of Xencor, Inc. (NASDAQ:XNCR) by 0.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,165,450 shares of the biopharmaceutical company’s stock after purchasing an additional 61,692 shares during the period. Vanguard Group Inc. owned about 10.03% of Xencor worth $109,703,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Primecap Management Co. CA lifted its position in shares of Xencor by 1.4% during the 3rd quarter. Primecap Management Co. CA now owns 10,675,022 shares of the biopharmaceutical company’s stock worth $125,218,000 after purchasing an additional 147,700 shares during the last quarter. SG Americas Securities LLC purchased a new stake in shares of Xencor during the 3rd quarter worth $1,062,000. Jefferies Financial Group Inc. purchased a new stake in shares of Xencor during the 3rd quarter worth $1,173,000. Baker BROS. Advisors LP lifted its position in shares of Xencor by 64.4% during the 3rd quarter. Baker BROS. Advisors LP now owns 1,102,106 shares of the biopharmaceutical company’s stock worth $12,928,000 after purchasing an additional 431,675 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its position in shares of Xencor by 21.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 401,501 shares of the biopharmaceutical company’s stock worth $4,710,000 after purchasing an additional 71,494 shares during the last quarter.

Insider Activity at Xencor

In other Xencor news, SVP Celia Eckert sold 3,244 shares of the business’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $11.25, for a total value of $36,495.00. Following the completion of the transaction, the senior vice president directly owned 78,685 shares in the company, valued at approximately $885,206.25. The trade was a 3.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP John R. Desjarlais sold 4,118 shares of the firm’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $11.25, for a total value of $46,327.50. Following the sale, the vice president owned 266,333 shares in the company, valued at $2,996,246.25. This trade represents a 1.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 44,020 shares of company stock valued at $499,817. Company insiders own 5.23% of the company’s stock.

Analyst Ratings Changes

XNCR has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xencor in a research report on Friday, March 27th. Zacks Research cut shares of Xencor from a “hold” rating to a “strong sell” rating in a research report on Wednesday, May 6th. Wall Street Zen cut shares of Xencor from a “hold” rating to a “strong sell” rating in a research report on Saturday. Barclays lifted their price objective on shares of Xencor from $26.00 to $27.00 and gave the stock an “overweight” rating in a research report on Thursday, February 26th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Xencor from $13.00 to $14.00 and gave the company a “neutral” rating in a research report on Monday. Six analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $24.50.

Xencor Trading Down 2.7%

Shares of XNCR opened at $12.44 on Wednesday. The firm has a market cap of $922.30 million, a PE ratio of -5.43 and a beta of 0.93. The company’s 50 day simple moving average is $12.27 and its 200-day simple moving average is $13.57. Xencor, Inc. has a 12-month low of $6.92 and a 12-month high of $18.69.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported ($1.71) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.96). The company had revenue of $4.52 million during the quarter, compared to analyst estimates of $27.86 million. Xencor had a negative net margin of 177.10% and a negative return on equity of 28.77%. The firm’s revenue for the quarter was down 86.2% on a year-over-year basis. During the same quarter last year, the business earned ($0.66) EPS. As a group, equities research analysts forecast that Xencor, Inc. will post -3.56 EPS for the current fiscal year.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.